Targeted therapies (such as anti-angiogenic drugs and EGFR inhibitors) inhibit tumor progression by specifically blocking tumor growth signals or angiogenesis, but they are prone to developing resistance and may not sufficiently sensitize tumors to radiotherapy (Chen et al., 2015). Here, EGFR is linked to neoplasm.